A PepGen drug in development for myotonic dystrophy type 1 (DM1) has encouraging early human data that suggest it could be a better treatment than other medicines in clinical testing for this rare ...

The drug's potential to target the underlying cause of DM1, a genetic disorder affecting muscles and other systems, could offer a new therapeutic option for patients with no approved treatments ...

This level of correction, observed at 28 days post-dosing, is notable compared to multi-dose trials of similar duration. The drug’s potential to target the underlying cause of DM1, a genetic disorder ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

Arrakis’s DM1 drug program represents a rationally designed small molecule genetic medicine directed at a pathogenic RNA to achieve reversal of myotonia in an animal model of DM1. Utilizing the ...

Details of the presentation are as follows: Arrakis’s DM1 drug program represents a rationally designed small molecule genetic medicine directed at a pathogenic RNA to achieve reversal of ...

BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...

Dyne Therapeutics (NASDAQ:DYN) traded higher in the premarket on Wednesday after BMO Capital Markets launched its coverage with an Outperform recommendation and a $50 per share target, citing the ...

Myotonic dystrophy type 1 (DM1), a genetic disorder, shares overlapping features with chronic kidney disease, including ...

Thurman M. Wheeler, MD, of the Department of Neurology at Massachusetts General Hospital, is the senior author of a paper published in Nature Communications, "Analysis of human urinary extracellular ...

(Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological ...